Care Access had disagreed with Pfizer and Valneva’s decision to remove more than 3,000 participants from the study over alleged violations of Good Clinical Practice, an international ethical and scientific standard clinical researchers must follow during trials.
But the setback forced the company to restructure about two months later, leading to layoffs for about half of its staff, according to reporting by Endpoints News.
